Immune & Thymic · Research deep dive
LL-37: the cited literature
Every study referenced in the LL-37 monograph, with plain-language context, PubMed links to read each paper yourself, and how the compound appears in the dosing literature.
How this compound is studied
Across the dosing literature, LL-37 is studied at 100 mcg – 500 mcg per administration, typically once daily in short courses. The reference walkthrough below maps each citation to what it actually showed.
References covered
LL-37 in wound healing: a phase 2 trial in venous leg ulcers
J. Invest. Dermatol., 2014
The full walkthrough is for subscribers
Unlock the evidence grading, what each study actually found, how the trials dosed it, reported safety signals, open questions, and PubMed links for LL-37.